Author Claim Review

 Quick Explanation Copied

 Long Explanation

Publication Profile & Citation Metrics

Kimsor Hong (ORCID 0009-0002-6537-8058) has 16 works, 112 citations, and an h-index of 7, with citation output accelerating recently (47 cites in 2025, 60 in 2026 per OpenAlex counts-by-year), suggesting growing — but still early — scholarly impact. Affiliation is listed as Second Xiangya Hospital of Central South University, though OpenAlex lists no primary institution.

Research Focus and Contribution Pattern

Hong's work centers on systemic lupus erythematosus, mesenchymal stem cell (MSC)-derived extracellular vesicles/secretomes, CAR-T cell therapy for autoimmunity, and microglia/EV neurobiology. The highest-impact output is an experimental study of hUCMSC-EVs in lupus nephritis in Stem Cell Research & Therapy (35 citations) where Hong is a middle author, and a first-author umbrella review plus Mendelian randomization analysis of omega-3 fatty acids and autoimmune disease in Autoimmunity Reviews (27 citations).

Most other outputs are narrative reviews — on CAR-T therapy in autoimmunity, double-negative B cells in SLE, iMSCs/iMSC-EVs, MSC secretomes in neonatal BPD/NEC, microglia EVs, and T cell exhaustion in SLE — largely as middle author within a consistent, prolific group (Wu, Mao, Zhu, Xie, Wen, et al.). One outlier is a GaN semiconductor growth spectral reflectance paper, suggesting either a name-collision entity or an atypical early contribution. One review (ADAM17 in PCOS) appeared in a low-visibility journal (Journal of Health Science and Medical Therapy), a minor quality flag.

Critical Assessment

• Strengths: rapid publication cadence, coherent SLE/immunology focus, first-authorship on a methodologically demanding umbrella review + MR study, publication in respected venues (Autoimmunity Reviews, Stem Cell Research & Therapy, Neurobiology of Disease).
• Weaknesses/blindspots: citation impact is modest and dominated by recent work (h-index 7 is typical of a trainee); heavy reliance on narrative reviews rather than primary research or independent first-author experimental studies; middle-authorship pattern limits attribution of leadership; open-access-heavy review output may inflate visibility relative to original contribution.
• Uncertainty: the lacking institutional profile and the GaN paper introduce some identity ambiguity in bibliometric aggregation.

 BGPT Author Review

Scientific Quality

Early-career researcher with h-index 7 and 112 citations across 16 works, mostly reviews as a middle author in a large group at Second Xiangya. One first-author umbrella review + MR analysis shows methodological breadth, but original experimental leadership is unproven; citation impact is modest and venue quality is mixed.

Communication Quality

Review titles are descriptive and clearly scoped, and publications appear in readable, well-indexed journals, but the assessment rests on titles/metadata rather than full-text evaluation of writing clarity.

Author Novelty

Topics (MSC-EVs, CAR-T for autoimmunity, T cell exhaustion in SLE) are active but crowded; the quadrant framework for donor age/sex in MSC secretomes and the omega-3 umbrella review + MR combination show some fresh synthesis, not fundamental novelty.

Scientific Rigor

The first-author umbrella review with Mendelian randomization indicates training in evidence synthesis and causal-inference methods with substantial reference lists (77-328 references), but most outputs are narrative reviews, which are lower-evidence-tier; the PCOS review in a weak journal is a rigor red flag.